Swedish Orphan Biovitrum AB: Sobi Q1 2026 report: Strong execution and pipeline momentum

AI Briefing

• – Sobi reports 24% increase in total revenue in Q1 2026, strong execution and pipeline momentum.
• – The company's pipeline continues to grow with multiple ongoing and planned trials.
• – Sobi's focus on rare disease treatment and vaccine development driving growth.